Abstract：[Abstract] Objective To discuss the clinical therapy effect and safety degree of type Ⅱ diabetic nephropathy by the intervention treatment of Sanqi Panaxnotoginseng Injection combined with Gliclazide and Melbine. Methods From September 2011 to December 2014, in Department of Endocrinology, the Fourth Affiliated Hospital of Guangxi Medical University, 80 patients with diabetic nephropathy (DN) were selected as research subjects, all of them belonged to the newest diagnosis standard of WHO of type Ⅱ diabetes patients and they were divided into observation group and control group according to random number table, with 40 patients in each group. The patients of two groups were educated with basic knowledge of diabetes before medical treatment, patients in control group were treated with Gliclazide sustained-release tablets by oral administration, 60 mg/time, 3 times/d and metformin hydrochloride enteric coated tablets by oral administration, 0.5 g/time, 3 times/d; patients in observation group were treated with injection of Sanqi Panaxnotoginseng Injection as supplement, 10 mL/time, twice/d. The therapy period involved three weeks. Before and after the therapy, all of the blood flow indexes, coagulation indexes, excretion of urinary protein and adverse reaction were recorded. Results After the therapy, patients in observation group had significant improvements in low shear blood viscosity, plasma viscosity and red cell assembling index, the differences were statistically significant (P < 0.05); the coagulation indexes of patients in observation group recovered to within the range of reference value and displayed great improvement compared with that of control group, the differences were statistically significant (P < 0.05); the urinary albumin excretion rate of patients in observation group were lower compared with that of control group, the differences were statistically significant (P < 0.05), while the testing result of serum creatinine of two groups, the differences was not statistically significant (P > 0.05). During the three-week therapy period patients from both groups showed no adverse effect. Conclusion There is good therapy effect and high safety degree of intervention treating type Ⅱ diabetic nephropathy with Sanqi Panaxnotoginseng Injection, which deserves further development.
京公网安备 11010502046598号